The Phase 1, Open-label, PET Trial Designed to Investigate the Effect of AZD2389 on FAP Occupancy in the Liver in Participants With Advanced Liver Fibrosis.

• Status: RECRUITING
• Trial end date: 2026-02-19

Summary

This is a phase 1, open-label, PET trial. The study is designed to investigate the effect of AZD2389 on FAP occupancy in the liver in participants with advanced liver fibrosis.

• Phase: PHASE1

Details

• Lead Sponsor: AstraZeneca
• Collaborators: CTC Clinical Trial Consultants AB; Karolinska Institutet
• Treatments: Positron-Emission Tomography